Key Metrics
CiteScore 

6.5
SNIP 

1.15
Recommended pre-submission checks
Powered by 

Lung Cancer: Targets and Therapy Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Lung Cancer: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Lung Cancer: Targets and Therapy
Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients
- 16 Mar 2026
- Lung Cancer: Targets and Therapy
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China.
- 1 Feb 2026
- Lung Cancer (Auckland, N.Z.)
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer
- 6 Jan 2026
- Lung Cancer: Targets and Therapy
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
- 25 Dec 2025
- Lung Cancer: Targets and Therapy
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
- 16 Dec 2025
- Lung Cancer: Targets and Therapy
Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker
- 10 Dec 2025
- Lung Cancer: Targets and Therapy
Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients
- 16 Mar 2026
- Lung Cancer: Targets and Therapy
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China.
- 1 Feb 2026
- Lung Cancer (Auckland, N.Z.)
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer
- 6 Jan 2026
- Lung Cancer: Targets and Therapy
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
- 25 Dec 2025
- Lung Cancer: Targets and Therapy
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
- 16 Dec 2025
- Lung Cancer: Targets and Therapy
Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker
- 10 Dec 2025
- Lung Cancer: Targets and Therapy